Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

New research shows how myalgic encephalomyelitis/chronic fatigue syndrome disrupts interactions between the microbiome, ...